MoonLake is a cash-burning pre-profitability biotech trading 25% below the analyst consensus price target, with quality metrics below the minimum investable floor and a persistent earnings miss pattern — the primary signal is a structural quality disqualification that argues for exiting existing positions rather than adding.
Thesis pillars
- Quality Below Minimum Floor↓Deteriorating
- Bearish Options Positioning High Iv↓Deteriorating
- Persistent Earnings Miss Pattern↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 25, 2026· older than 90 days
MoonLake Immunotherapeutics (MLTX) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $11.56: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 2.35; Below-average business quality.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a single tri-specific Nanobody licensed from Merck Healthcare KGaA (MHKDG), to treat IL-17A/F-driven inflammatory diseases including hidradenitis suppurativa, psoriatic arthritis, axial... Read more
Sell if holding. Engine safety override at $11.56: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 2.35; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 60. Score 5.0/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated Nov 4, 2026Recent Developments — MoonLake Immunotherapeutics
Latest news
- NEWS MoonLake Immunotherapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai Nov 4, 2026
- NEWS MoonLake Q3 EPS $(0.93) Misses $(0.78) Estimate — benzinga Nov 4, 2026 negative
- NEWS What's Going On with MoonLake Immunotherapeutics Stock on Thursday? — benzinga Oct 22, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Thursday's Intraday Session — benzinga Oct 22, 2026 neutral
- NEWS Watching MoonLake Immunotherapeutics; Shares Trading Higher After AbbVie Reports Phase 3 INTREPID Results For Competing — benzinga Oct 22, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:59:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineSLK10-K Item 1: 'We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG'
- HIGHcounterpartyMHKDG license10-K Item 1A: 'Our business relies on certain licensing rights from MHKDG and RCT that can be terminated in certain circumstances.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.56: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 2.35; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 60. Prior stop was $10.75. Score 5.0/10, moderate confidence.
Analyst target: $24.83 (+114.8% upside). Prior stop was $10.75. Stop-loss: $10.75.
Concentration risk — Pipeline: SLK; Concentration risk — Counterparty: MHKDG license; Quality below floor (1.6 < 4.0).
MoonLake Immunotherapeutics trades at a P/E of N/A (forward -3.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts rate MLTX, with a consensus score of 4.0/5. 13 analysts publish price targets averaging $29.
What does MoonLake Immunotherapeutics do?MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a single tri-specific Nanobody...
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a single tri-specific Nanobody licensed from Merck Healthcare KGaA (MHKDG), to treat IL-17A/F-driven inflammatory diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis. The company has no products approved for commercial sale and reported a net loss of $230.3 million in 2025, with a planned BLA submission for SLK in HS expected in the second half of 2026 and a potential U.S. commercial launch in the second half of 2027.